Cargando…

National medicines policies – a review of the evolution and development processes

OBJECTIVES: Continuous provision of appropriate medicines of assured quality, in adequate quantities, and at reasonable prices is a concern for all national governments. A national medicines policy (NMP) developed in a collaborative fashion identifies strategies needed to meet these objectives and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoebert, Joëlle M, van Dijk, Liset, Mantel-Teeuwisse, Aukje K, Leufkens, Hubert GM, Laing, Richard O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987068/ https://www.ncbi.nlm.nih.gov/pubmed/24764540 http://dx.doi.org/10.1186/2052-3211-6-5

Ejemplares similares

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries
por: Leopold, Christine, et al.
Publicado: (2014)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Variability in market uptake of psychotropic medications in Europe reflects cultural diversity
por: Hoebert, J. M., et al.
Publicado: (2017)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Marketing of medicines in primary care: An analysis of direct marketing mailings and advertisements
por: Dankers, Marloes, et al.
Publicado: (2023)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Health policy and systems research in access to medicines: a prioritized agenda for low- and middle-income countries
por: Bigdeli, Maryam, et al.
Publicado: (2013)

Medicine shortages: impact behind numbers
por: Postma, Doerine J., et al.
Publicado: (2023)

Impact of medicine shortages on patients - a framework and application in the Netherlands
por: Postma, Doerine J., et al.
Publicado: (2022)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
por: Dankers, Marloes, et al.
Publicado: (2022)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
por: Kibira, Denis, et al.
Publicado: (2021)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2013)

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort
por: Sagwa, Evans L., et al.
Publicado: (2015)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
por: Willemen, Marjolein J., et al.
Publicado: (2011)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

Linking market authorizations of medicines with disease burden in South Africa
por: Narsai, K., et al.
Publicado: (2021)

Systematic reviews of ten pharmaceutical pricing policies – a research protocol
por: Tordrup, David, et al.
Publicado: (2020)

Post‐marketing dosing changes in the label of biologicals
por: Minnema, Lotte A., et al.
Publicado: (2019)

Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia
por: Kibira, Denis, et al.
Publicado: (2021)

Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana
por: Tetteh, Raymond A., et al.
Publicado: (2015)

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
por: Tetteh, Raymond A., et al.
Publicado: (2016)

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
por: Nartey, Edmund T., et al.
Publicado: (2019)

Sustainable Development Goal indicator for measuring availability and affordability of medicines for children: a proof-of-concept study
por: Joosse, Iris R, et al.
Publicado: (2023)

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses
por: Leopold, Christine, et al.
Publicado: (2014)

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
por: Ebbers, Hans C., et al.
Publicado: (2012)

Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts
por: Hogervorst, Milou A, et al.
Publicado: (2023)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cuefg7j7n3hoqolf855tetkt5p